Finance Watch: Two Biopharma IPOs Bring US Total To 17

Dianthus Raises $72m As It Closes Reverse Merger

Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.

Finance Watch Public Company
• Source: Alamy

After a month and a half initial public offering drought, two biopharmaceutical companies – Neumora Therapeutics, Inc. and RayzeBio, Inc. – launched IPOs in the US and grossed $561m combined on 14 September, in two of the largest first-time offerings this year.

Neumora sold 14.7 million shares at $17 each to gross $250m, which was in the middle of a proposed $16...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.